Researchers have uncovered promising evidence that intermittent fasting may play a crucial role in preventing blood clots. The study, involving 160 participants with coronary artery disease, revealed that this dietary approach appears to inhibit platelet activation and clot formation. Over a ten-day intervention period, researchers observed significant changes in the participants and their platelet activity.
Participants in the study were divided into two groups: one group practiced intermittent fasting, while the other followed an ad libitum diet. The results showed higher levels of indolepropionic acid (IPA) in the serum of those who engaged in intermittent fasting. IPA, a gut metabolite primarily produced by the bacteria C. sporogenes in mice, displayed remarkable antithrombotic efficacy comparable to clopidogrel, a commonly used antiplatelet medication.
In a parallel experiment with mice, those that underwent intermittent fasting exhibited increased levels of C. sporogenes and subsequently higher IPA levels. Researchers administered IPA injections to these mice, resulting in prolonged clotting times akin to the effects of a 5 mg/kg dose of clopidogrel. Further analysis indicated that IPA acts on the pregnane X receptor component of platelets to influence activation, linking its effect to specific signaling pathways.
“Intermittent fasting not only promotes a healthy gut bacteria population, as demonstrated in this study, but also leads to significant weight reduction, improved diabetes control and insulin sensitivity, and reduced inflammation in the body. To further enhance gut health, a diet rich in fiber, leafy greens, legumes, and yogurt provides an optimal environment for beneficial bacteria to thrive.” — Patrick Kee, M.D., Ph.D
The study excluded participants who had been on antiplatelet medications recently or those with conditions such as anemia or heart failure. This ensured the results purely reflected the impact of intermittent fasting without external influences. While the effects were notable in humans, they were even more pronounced in mice that received both IPA and clopidogrel.
The findings suggest that intermittent fasting may offer a novel approach to managing platelet activation and clot formation in individuals with coronary artery disease. However, the study's short duration leaves questions about the long-term effects unanswered. Researchers emphasize the need for extended trials to understand the sustained impact of intermittent fasting on human health.
Leave a Reply